ArticleJACC. Case reports2026
Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted therapies like tyrosine kinase inhibitors have significantly improved outcomes in non-small cell lung cancer. Entrectinib, a multikinase inhibitor, showed efficacy in ROS1 fusion-positive NSCLC, including intracranial metastases. Although generally well tolerated, rare but serious cardiac adverse effects have been reported. CASE SUMMARY: We report a 51-year-old woman with ROS1-mutant metastatic non-small cell lung cancer who developed symptomatic sinus bradycardia during entrectinib therapy. After disease progression on crizotinib, lorlatinib, and reprotrectinib, she was started on entrectinib. Within 1 week, she developed marked bradycardia (38-48 beats/min) with lightheadedness. Electrocardiogram and echocardiography confirmed sinus bradycardia with mildly reduced ejection fraction. Entrectinib was discontinued, and symptoms resolved with heart rate normalization. TAKE-HOME MESSAGES: Sinus bradycardia may be a rare but significant side effect of entrectinib, possibly related to ALK inhibition. Cardiac monitoring and multidisciplinary management are essential when initiating therapy with ALK/ROS1 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.